共 373 条
[1]
Louis DN(2007)The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 97-109
[2]
Ohgaki H(2013)Molecular neuro-oncology in clinical practice: a new horizon Lancet Oncol 14 e370-e379
[3]
Wiestler OD(2013)Predictive biomarkers in adult gliomas: the present and the future Curr Opin Oncol 25 689-694
[4]
Cavenee WK(2009)Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Acta Neuropathol 118 469-474
[5]
Burger PC(2011)The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations Brain Pathol 21 74-87
[6]
Jouvet A(2009)IDH1 and IDH2 mutations in gliomas N Engl J Med 360 765-773
[7]
Scheithauer BW(2011)Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology Acta Neuropathol 121 241-252
[8]
Kleihues P(2010)IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Clin Cancer Res 16 1597-1604
[9]
Weller M(2009)IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide Neurology 73 1792-1795
[10]
Pfister SM(2010)IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas Neurology 75 1560-1566